Suramin is synergistic with vinblastine in human colonic tumor cell lines: Effect of cell density and timing of drug delivery

Anticancer Research

Volumn 17, Issue 3 C, 1997, Pages 2065-2071

  Frommel, Thomas O ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Colon cancer; Multidrug resistance; Suramin

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; SURAMIN; VINBLASTINE;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL COUNT; CELL DENSITY; CELL PROLIFERATION; COLON TUMOR; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL SURVIVAL; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; KINETICS; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; SURAMIN; TIME FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0030795046     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Eisenberger M and Reyno L: Suramin. Cancer Treat Rev 20: 259-273, 1994.
2. Scher HI: Suramin: Here to stay? J Natl Cancer Inst 85: 594-597, 1993.
3. Stein C: Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53: 2239-2248, 1993.
4. Frommel T and Balber A: Flow cytometric analysis of drug accumulation by multidrug-resistant Trypanosoma brucei brucei and T. b. rhodesiense. Mol Biochem 'Parasitol 26: 183-192, 1987.
5. Fruehauf J, Myers C and Sinha B: Synergistic activity of suramin with tumor necrosis factor α and doxorubicin on human prostate cancer cell lines. J Natl Cancer Inst 82: 1206-1209, 1990.
6. Lopez R, van Rijswijk R, Wagstaff J, Pinedo H and Peters G: The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumor effects 'of suramin. Eur J Cancer 30: 1545-1549, 1994.
7. Lopez R, Peters G, Smitskamp-Wilms E, Virizuela J, Ark-Otte J, Pinedo H and Giaccone G: In vitro sequence-dependent synergistic effect of suramin and camptothecin. Eur J Cancer 30: 1670-1674, 1994.
8. Falcone A, Danesi R, Zaccaro L, Pieracci D, Pfanner E, Cianci C, Andreuccetti M, Malvadi G, DelTacca M and Conte P: Synergistic antiproliferative activity of suramin and α2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies. Eur J Cancer 30: 516-520, 1994.
9. Ford J and Hait W: Pharmacology of drugs that alter multidrug resistance. Pharm Rev 42: 155-199, 1990.
10. Chaudhary P and Roninson I: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85: 632-639, 1993.
11. Chambers TC, McAvoy EM, Jacobs JW and Elion G: Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem 265: 7679-7686, 1990.
12. Lindman H, Taube A and Bergh J: Suramin inhibits the growth of human breast cancer cell lines. Studies on parental lines and corresponding sublines with acquired doxorubicin resistance with and without expression of P-glycoprotein. Anticancer Res 14: 363-366, 1994.
13. Frommel T, Coon J, Tsuruo T and Roninson I: Variable effects of sodium butyrate on the expression and function of the mdr1 (P-glycoprotein) gene in colon carcinoma cell lines. Int J Cancer 55: 297-302, 1993.
14. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J and DeClercq E: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Meth 20: 309-321, 1988.
15. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
16. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD and Roninson IB: Quantitative analysis of mdr1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87: 7160-7164, 1990.
17. Hickman J: Apoptosis induced by anticancer drugs. Cancer Metast Rev 11: 121-139, 1992.
18. Dive C, Evans C and Whetton A: Induction of apoptosis - new targets for cancer chemotherapy. Sem Cancer Biol 3: 417-427, 1992.
19. 1 checkpoint. Clin Cancer Res 2: 269-276, 1996.
20. Tu S-M, McConnell K, Marin MC, Campbell ML, Fernandez A, Von Eschenbach AC and McDonnell TJ: Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Lett 93: 147-155, 1995.
21. Cardinelli M, Sartor O and Robbins K: Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes the growth of certain malignant cells. J Clin Invest 89: 1242-1247, 1992.
22. Mitchen J, Rago R and Wilding G: Effects of suramin on the proliferation of primary epithelial cell cultures derived from normal, benign hyperplastic and cancerous human prostates. Prostate 22: 75-89, 1993.
23. Foekens J, Sieuwerts A, Stuurman-Smeets E, Dorssers L, Berns E and Klijn G: Pleiotropic actions of suramin on the proliferation of human breast-cancer cells in vitro. Int J Cancer 51: 439-444, 1992.
24. Takano S, Gately S, Neville M, Herblin W, Gross J. Engelhard H, Perricone M, Eidsvoog K and Brem S: Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 54: 2654-2660, 1994.
25. Stein C, LaRocca R, McAtee N, Thomas R, Horne M and Myers C: Suramin - an anticancer drug with a unique mechanism of action. J Clin Oncol 7: 499-508, 1988.
26. Olivier S, Formento P, Fischel JL, Etienne MC and Milano G: Epidermal growth factor receptor expression and suramin cytotoxicity in vitro. Eur J Cancer 26: 867-871, 1990.
27. Yamazaki H, Dilworth A, Myers CE and Sinha BK: Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro. Prostate 23: 25-36, 1993.
28. Mahoney C, Azzi A and Huang K: Effects of suramin, an anti-human immunodeficiency virus reverse transcriptase agent, on protein kinase C. J Biol Chem 265: 5424-5428, 1990
29. Hensey C, Boscoboinik D and Azzi A: Suramin, an anticancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett 258: 156-158, 1989.
30. Fantini J, Rognoni J-B, Roccabianca M, Pommier G and Marvaldi J: Suramin inhibits cell growth and glycolytic activity and triggers differentiation of human colic adenocarcinoma cell clone HT29-D4. J Biol Chem 264: 10282-10286, 1989.
31. Taylor C, Lui R, Fanta P and Salmon S: Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst 84: 489-494, 1992.